SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

From left: Editas CMO Baisong Mei and CEO Gilmore
Drug Development
Editas Hits Pause on LCA10 Program in Search of Partner
Editas Medicine is pausing its ocular gene therapy program after demonstrating a favorable safety profile and seeking a potential partner to develop EDIT-101, the company announced Thursday.
November 17, 2022
 · 
1 min read
 · 
Kate Goodwin
Abandoned Bayer Drug Shows Preclinical Promise for Childhood Brain Tumors
New research out of McMaster University found a recently abandoned Bayer compound halted the growth of an aggressive form of pediatric medulloblastoma in mouse models.
November 17, 2022
 · 
4 min read
 · 
Kate Goodwin
Courtesy of Stoke Therapeutics
Drug Development
Stoke Looks to Pivotal Trial for Dravet Candidate
Stoke Therapeutics is gearing up for a pivotal trial of its lead program for a rare genetic epilepsy disease and announced positive results from its Phase I/IIa study in children with Dravet syndrome.
November 14, 2022
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Novel Gene Therapy Approaches for Solid Tumors on Display at SITC
PACT Pharma shared results of a first-of-its-kind trial using CRISPR technology to swap a gene in a patient’s immune cell to treat solid tumors.
November 11, 2022
 · 
3 min read
 · 
Kate Goodwin
David R. Epstein, CEO of Seagen, Courtesy Bloomber
Business
Seagen Begins New Chapter with Novartis Vet David Epstein at the Helm
After six months of searching for its next chief executive, Washington’s largest biotech firm has found its match. On Thursday, Seagen named David R. Epstein as CEO.
November 10, 2022
 · 
2 min read
 · 
Kate Goodwin
Prof Seth Masters, VP Discovery Biology at NRG The
Drug Development
NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson’s, ALS
With a fresh $18 million in the bank, NRG Therapeutics is ready to put its novel mitochondrial approach to the test for devastating neurodegenerative disorders—Parkinson’s and ALS.
November 9, 2022
 · 
2 min read
 · 
Kate Goodwin
Sarah Silbiger/Getty Images
Drug Development
Verve and Beam Face Regulatory Roadblocks with Next-Gen Base Editors
Verve Therapeutics’ base editing program has been forced into a detour after the FDA placed a hold on its investigational new drug application. Beam has also posted its own regulatory update.
November 7, 2022
 · 
3 min read
 · 
Kate Goodwin
Business
Bayer Returns Thrombosis Drug to Ionis Despite Positive Phase II Results
In spite of positive Phase IIb results from a thrombosis prevention trial, Ionis is back on the market for a new partner after Bayer returned the rights to the drug to Ionis.
November 4, 2022
 · 
2 min read
 · 
Kate Goodwin
Pictured: Exelixis headquarters/Company courtesy
Drug Development
Exelixis Drops $100M on Two Collaborations to Expand Cancer Pipeline
Flush with cash from the growing success of its chemotherapy drug, Exelixis dropped $100M on two collaboration deals this week to invest in promising early clinical assets.
November 2, 2022
 · 
3 min read
 · 
Kate Goodwin
Young team during virus lab tests. Multi ethnic scientists focused on work. Wearing protective workwear
Drug Development
Positive AML Data Propels Actinium’s Pipeline as it Preps for BLA
Monday, Actinium Pharmaceuticals released promising results Monday from a Phase III trial studying its lead radiotherapy candidate, Iomab-B, for patients with relapsed or refractory AML.
October 31, 2022
 · 
3 min read
 · 
Kate Goodwin
Job Trends
Life Science Industry Set Record Pace in 2021
As we closed the books on year two of the COVID-19 pandemic, the Life Sciences market set records as the strongest in history.
February 28, 2022
 · 
2 min read
 · 
Kate Goodwin
Pictured: Red and white Lilly sign on building/Mic
FDA
Eli Lilly Diabetes Drug Notches Another Win in Competitive Space
Eli Lilly’s Jardiance scores expanded heart failure approval from the FDA and will now be available to all patients with heart failure to reduce the risk of death and hospitalization.
February 25, 2022
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Global Players Making Waves in MDD, Sanfilippo syndrome and SCLC
Biopharma companies are continuously working to test new treatments to the market. Here are three clinical updates announced this week, spanning three different continents.
February 24, 2022
 · 
2 min read
 · 
Kate Goodwin
Drug Development
Money on the Move: February 16–22
More biotech companies turn to private investors as the market churns volatile for life sciences. Here’s who’s scooping up the cash this week.
February 23, 2022
 · 
3 min read
 · 
Kate Goodwin
Drug Development
Synairgen Crashes as Inhaled COVID-19 Treatment Fails in Phase III
Synairgen watched its stock plummet 85% after reporting disappointing Phase III results for its inhaled COVID-19 treatment on Feb. 21.
February 22, 2022
 · 
2 min read
 · 
Kate Goodwin
Load More